GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alzamend Neuro Inc (NAS:ALZN) » Definitions » Long-Term Debt & Capital Lease Obligation

Alzamend Neuro (Alzamend Neuro) Long-Term Debt & Capital Lease Obligation : $0.00 Mil (As of Jan. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Alzamend Neuro Long-Term Debt & Capital Lease Obligation?

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Alzamend Neuro's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was $0.00 Mil.

LT-Debt-to-Total-Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligation divides by its Total Assets. Alzamend Neuro's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was $0.00 Mil. Alzamend Neuro's Total Assets for the quarter that ended in Jan. 2024 was $0.78 Mil. Alzamend Neuro's LT-Debt-to-Total-Asset for the quarter that ended in Jan. 2024 was 0.00.

Alzamend Neuro's LT-Debt-to-Total-Asset stayed the same from Jan. 2023 (0.00) to Jan. 2024 (0.00).


Alzamend Neuro Long-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Alzamend Neuro's Long-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alzamend Neuro Long-Term Debt & Capital Lease Obligation Chart

Alzamend Neuro Annual Data
Trend Apr19 Apr20 Apr21 Apr22 Apr23
Long-Term Debt & Capital Lease Obligation
- - - - -

Alzamend Neuro Quarterly Data
Apr19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Long-Term Debt & Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Alzamend Neuro Long-Term Debt & Capital Lease Obligation Calculation

Long-Term Debt is the debt due more than 12 months in the future. The debt can be owed to banks or bondholders. Some companies issue bonds to investors and pay interest on the bonds.

Long-Term Capital Lease Obligation represents the total liability for long-term leases lasting over one year. It's amount equal to the present value (the principal) at the beginning of the lease term less lease payments during the lease term.

The interest paid on companies' debt is reflected in the income statement as interest expense. If a company has too much debt and it cannot serve the interest payment on the debt or repay the matured debt, the company risks bankruptcy. Peter Lynch famously said: A company that does not have debt cannot go bankrupt.

A company's long term debt may have different dates of maturity and interest rates, depending on the terms.

Usually a company issues long term debt to pay for its capital expenditures. Borrowing allows the company to do things that otherwise cannot be done with only the capital it has. But debt can be risky.


Alzamend Neuro  (NAS:ALZN) Long-Term Debt & Capital Lease Obligation Explanation

LT-Debt-to-Total-Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Alzamend Neuro's LT-Debt-to-Total-Asset ratio for the quarter that ended in Jan. 2024 is calculated as:

LT-Debt-to-Total-Asset (Q: Jan. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Jan. 2024 )/Total Assets (Q: Jan. 2024 )
=0/0.783
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Buffett says that durable competitive advantages carry little to no long-term debt because the company is so profitable that even expansions or acquisitions are self financed.

We are interested in long term debt load for the last ten years. If the ten years of operation show little to no long term debt, then the company has some kind of strong competitive advantage.

Warren Buffett's historic purchases indicate that on any given year, the company should have sufficient yearly net earnings to pay all long term within 3 or 4 year earnings period. (e.g. Coke + Moody's = 1yr)

Companies with enough earning power to pay long term debt in less than 3 or 4 years is a good candidate in our search for long term competitive advantage.

BUT, these companies are targets for leveraged buy outs, which saddles the business with long term debt.

If all else indicates the company has a moat, but it has ton of debt, a leveraged buyout may have created the debt. In these cases the company's bonds offer the better bet, in that the company’s earnings power is focused on paying off the debt and not growth.

Important: little or no long term debt often means a Good Long Term Bet


Alzamend Neuro Long-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Alzamend Neuro's Long-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Alzamend Neuro (Alzamend Neuro) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alzamend Neuro Inc (NAS:ALZN) » Definitions » Long-Term Debt & Capital Lease Obligation
Traded in Other Exchanges
N/A
Address
3480 Peachtree Road NE, Second Floor Suite 103, Atlanta, GA, USA, 30326
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
Executives
Ault Milton C Iii 10 percent owner 11411 SOUTHERN HIGHLANDS PARKWAY, SUITE 240, LAS VEGAS NV 89141
David J Katzoff officer: Chief Operating Officer 201 SHIPYARD WAY, NEWPORT BEACH CA 92663
Stephan Jackman director, officer: Chief Executive Officer C/O ALZAMEND NEURO, INC., 3802 SPECTRUM BOULEVARD, SUITE 112C, TAMPA FL 33612
Lynne Fahey Mcgrath director 28145 CEDAR POINT RD., EASTON MD 21601
Mark Gustafson director 10691 ROSECROFT CRESCENT, RICHMOND A1 V7A 2H9
William B. Horne director C/O AULT ALLIANCE, INC., 940 SOUTH COAST DRIVE, SUITE 200, COSTA MESA CA 92626
Henry Carl Nisser director, officer: Exec VP and General Counsel 100 PARK AVENUE, SUITE 1658A, NEW YORK NY 10017
Kenneth S Cragun officer: SVP of Finance 3775 CHIPPEWA CIRCLE, CORONA CA 92881
Jeffrey Oram director 15 ORCHARD STREET, MENDHAM NJ 07945
Escalona Lien officer: Chief Financial Officer C/O ALZAMEND NEURO, INC., 3802 SPECTRUM BOULEVARD, SUITE 112C, TAMPA FL 33612
Andrew H. Woo director 2021 SANTA MONICA BLVD., SUITE 525E, SANTA MONICA CA 90404

Alzamend Neuro (Alzamend Neuro) Headlines

From GuruFocus

Alzamend Neuro to Present at Sequire Biotechnology Conference

By Business Wire Business Wire 01-26-2023